Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously.Wikipedia
|Normal Response Expected
|You do not appear to carry any G6PD mutations linked to an unwanted side effect (hemolytic anemia and methemoglobinemia).
|Use with Caution
|You carry a G6PD mutation that might lead to an unwanted side effect (hemolytic anemia and methemoglobinemia) when taking pegloticase; due to variable expression (i.e. in females), enzymatic testing for G6PD activity is advisable.
|You carry a G6PD mutation linked to an unwanted side effect (hemolytic anemia and methemoglobinemia) when taking pegloticase; pegloticase should not be prescribed for you according to the FDA.